Neurocrine Biosciences logged a -0.9% change during today's morning session, and is now trading at a price of $116.09 per share. The S&P 500 index moved -0.0%. NBIX's trading volume is 92,385 compared to the stock's average volume of 772,612.
Neurocrine Biosciences trades -9.36% away from its average analyst target price of $128.09 per share. The 22 analysts following the stock have set target prices ranging from $95.0 to $154.0, and on average have given Neurocrine Biosciences a rating of buy.
If you are considering an investment in NBIX, you'll want to know the following:
-
Neurocrine Biosciences's current price is 371.5% above its Graham number of $24.62, which implies that at its current valuation it does not offer a margin of safety
-
Neurocrine Biosciences has moved 11.0% over the last year, and the S&P 500 logged a change of 14.0%
-
Based on its trailing earnings per share of 1.79, Neurocrine Biosciences has a trailing 12 month Price to Earnings (P/E) ratio of 64.9 while the S&P 500 average is 15.97
-
NBIX has a forward P/E ratio of 24.3 based on its forward 12 month price to earnings (EPS) of $4.78 per share
-
The company has a price to earnings growth (PEG) ratio of 2.77 — a number near or below 1 signifying that Neurocrine Biosciences is fairly valued compared to its estimated growth potential
-
Its Price to Book (P/B) ratio is 6.11 compared to its sector average of 4.16
-
Neurocrine Biosciences, Inc. discovers, develops, and markets pharmaceuticals for neurological, endocrine, and psychiatric disorders.
-
Based in San Diego, the company has 1,350 full time employees and a market cap of $11.34 Billion.